234 related articles for article (PubMed ID: 25196601)
1. Adoptive immunotherapy strategies with cytokine-induced killer (CIK) cells in the treatment of hematological malignancies.
Schmeel FC; Schmeel LC; Gast SM; Schmidt-Wolf IG
Int J Mol Sci; 2014 Aug; 15(8):14632-48. PubMed ID: 25196601
[TBL] [Abstract][Full Text] [Related]
2. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation.
Laport GG; Sheehan K; Baker J; Armstrong R; Wong RM; Lowsky R; Johnston LJ; Shizuru JA; Miklos D; Arai S; Benjamin JE; Weng WK; Negrin RS
Biol Blood Marrow Transplant; 2011 Nov; 17(11):1679-87. PubMed ID: 21664472
[TBL] [Abstract][Full Text] [Related]
3. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
[TBL] [Abstract][Full Text] [Related]
4. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
[TBL] [Abstract][Full Text] [Related]
5. Ten-year update of the international registry on cytokine-induced killer cells in cancer immunotherapy.
Zhang Y; Schmidt-Wolf IGH
J Cell Physiol; 2020 Dec; 235(12):9291-9303. PubMed ID: 32484595
[TBL] [Abstract][Full Text] [Related]
6. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors.
Mesiano G; Todorovic M; Gammaitoni L; Leuci V; Giraudo Diego L; Carnevale-Schianca F; Fagioli F; Piacibello W; Aglietta M; Sangiolo D
Expert Opin Biol Ther; 2012 Jun; 12(6):673-84. PubMed ID: 22500889
[TBL] [Abstract][Full Text] [Related]
7. Increase in Efficacy of Checkpoint Inhibition by Cytokine-Induced-Killer Cells as a Combination Immunotherapy for Renal Cancer.
Dehno MN; Li Y; Weiher H; Schmidt-Wolf IGH
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32349280
[TBL] [Abstract][Full Text] [Related]
8. [Application of immune function test to evaluate effect of cytokine-induced autologous killer cell infusion for elderly patients with hematological malignancies].
Cai LL; Yang B; Lu XC; Zhu HL; Han WD; Wang Y; Liu Y; Dai HR; Yao SQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1250-5. PubMed ID: 21129270
[TBL] [Abstract][Full Text] [Related]
9. How can Cytokine-induced killer cells overcome CAR-T cell limits.
Cappuzzello E; Vigolo E; D'Accardio G; Astori G; Rosato A; Sommaggio R
Front Immunol; 2023; 14():1229540. PubMed ID: 37675107
[TBL] [Abstract][Full Text] [Related]
10. Cytokine-induced killer cells/dendritic cells-cytokine induced killer cells immunotherapy combined with chemotherapy for treatment of colorectal cancer in China: a meta-analysis of 29 trials involving 2,610 patients.
Zhang L; Mu Y; Zhang A; Xie J; Chen S; Xu F; Wang W; Zhang Y; Ren S; Zhou C
Oncotarget; 2017 Jul; 8(28):45164-45177. PubMed ID: 28404886
[TBL] [Abstract][Full Text] [Related]
11. Cancer Immunotherapy with Cytokine-Induced Killer Cells.
Mata-Molanes JJ; Sureda González M; Valenzuela Jiménez B; Martínez Navarro EM; Brugarolas Masllorens A
Target Oncol; 2017 Jun; 12(3):289-299. PubMed ID: 28474278
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of cord blood-derived cytokine-induced killer cells in treatment of patients with malignancies.
Zhang Z; Wang L; Luo Z; Zhao X; Huang J; Li H; Yang S; Zhao X; Zhang L; Li L; Wang F; Huang L; Zhang Y
Cytotherapy; 2015 Aug; 17(8):1130-8. PubMed ID: 25963952
[TBL] [Abstract][Full Text] [Related]
13. CIK as therapeutic agents against tumors.
Introna M
J Autoimmun; 2017 Dec; 85():32-44. PubMed ID: 28679475
[TBL] [Abstract][Full Text] [Related]
14. ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma.
Merker M; Wagner J; Kreyenberg H; Heim C; Moser LM; Wels WS; Bonig H; Ivics Z; Ullrich E; Klingebiel T; Bader P; Rettinger E
Front Immunol; 2020; 11():581468. PubMed ID: 33193388
[TBL] [Abstract][Full Text] [Related]
15. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models.
Shi S; Wang R; Chen Y; Song H; Chen L; Huang G
PLoS One; 2013; 8(6):e65757. PubMed ID: 23799045
[TBL] [Abstract][Full Text] [Related]
16. Cell-based immunotherapy with cytokine-induced killer (CIK) cells: From preparation and testing to clinical application.
Meng Y; Yu Z; Wu Y; Du T; Chen S; Meng F; Su N; Ma Y; Li X; Sun S; Zhang G
Hum Vaccin Immunother; 2017 Jun; 13(6):1-9. PubMed ID: 28301281
[TBL] [Abstract][Full Text] [Related]
17. Clinical effect and safety of dendritic cell-cytokine-induced killer cell immunotherapy for pancreatic cancer: a systematic review and meta-analysis.
Liu YL; Yang LX; Zhang F; Tang BS; Zhao LT; Zhu JR; Jin QY; Wang RX; Li YM
Cytotherapy; 2019 Oct; 21(10):1064-1080. PubMed ID: 31462394
[TBL] [Abstract][Full Text] [Related]
18. An update on new adoptive immunotherapy strategies for solid tumors with cytokine-induced killer cells.
Jäkel CE; Schmidt-Wolf IG
Expert Opin Biol Ther; 2014 Jul; 14(7):905-16. PubMed ID: 24673175
[TBL] [Abstract][Full Text] [Related]
19. [Research Progress on Dendritic Cells Combined with Cytokine Induced Killer Cells Immunotherapy for Hematological Malignancies --Review].
Shi J; Ma TT; Liu HS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Aug; 26(4):1235-1239. PubMed ID: 30111437
[TBL] [Abstract][Full Text] [Related]
20. Toll-like receptor 4 is required for the cytotoxicity of cytokine-induced killer cells.
Cai C; Chen W; Miao D; Cheng L; Yang G; Zhang L; Li Y; Zhang L
Acta Haematol; 2014; 132(1):5-9. PubMed ID: 24356089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
